Q-omics provides the consensus-scored GLP2R profile across patient tissues and cancer cell-line models. GLP2R expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GLP2R is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, GLP2R RNA expression shows 19,478 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where GLP2R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLP2R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLP2R survival associations across molecular data types. GLP2R RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLP2R RNA expression–survival associations across cancer types. High GLP2R expression shows unfavorable associations in ACC, STAD, KIRC, LUAD and LIHC, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GLP2R RNA expression.
This table summarizes GLP2R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GLP2R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLP2R shows lower tumor expression in COAD, BLCA, READ, THCA, BRCA and STAD. The COAD box plot shows higher GLP2R RNA expression in normal versus tumor tissue (log2 FC = −2.306, t-test p < 0.001).
This table shows molecular features associated with GLP2R in patient tissues and cancer cell lines. In patient samples, GLP2R shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GLP2R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
